The interplay between IL-31, IL-33, eosinophils, and the tumor microenvironment (TME) could significantly influence immunotherapy outcomes in NSCLC, and understanding these mechanisms is crucial for enhancing therapeutic efficacy and overcoming treatment resistance. The gene discussed is IL33; the disease is non-small cell lung carcinoma.